Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
Tóm tắt
Từ khóa
Tài liệu tham khảo
J.D. Watson, N.H. Hopkins, J.W. Roberts, J.A. Steitz, A.M. Weiner, Molecular Biology of the Gene, Benjamin/Cummings, Menlo Park, CA, 1987.
Osheroff, 1989, Biochemical basis for the interactions of type I and type II topoisomerases with DNA, Pharmacol. Ther., 41, 223, 10.1016/0163-7258(89)90108-3
Osheroff, 1991, Catalytic function of DNA topoisomerase II, BioEssays, 13, 269, 10.1002/bies.950130603
Berger, 1998, Type II DNA topoisomerases, Curr. Opin. Sruct. Biol., 8, 26, 10.1016/S0959-440X(98)80006-7
N.R. Cozzarelli, J.C. Wang, DNA Topology and its Biological Effects, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1990.
Watt, 1994, Structure and function of type II DNA topoisomerases, Biochem. J., 303, 681, 10.1042/bj3030681
Hsieh, 1980, ATP-dependent DNA topoisomerase from D. melanogaster reversibly catenates duplex DNA rings, Cell, 21, 115, 10.1016/0092-8674(80)90119-1
Liu, 1980, Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break, Cell, 19, 697, 10.1016/S0092-8674(80)80046-8
Liu, 1983, Cleavage of DNA by mammalian DNA topoisomerase II, J. Biol. Chem., 258, 15365, 10.1016/S0021-9258(17)43815-4
Rowe, 1986, DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II, Cancer Res., 46, 2021
Zechiedrich, 1989, Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate, Biochemistry, 28, 6229, 10.1021/bi00441a014
Sander, 1983, Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster, J. Biol. Chem., 258, 8421, 10.1016/S0021-9258(20)82081-X
Lindsley, 1991, Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding, Proc. Natl. Acad. Sci. USA, 88, 10485, 10.1073/pnas.88.23.10485
Osheroff, 1983, DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA, J. Biol. Chem., 258, 9536, 10.1016/S0021-9258(17)44700-4
Capranico, 1992, DNA topoisomerase-trapping antitumour drugs, Eur. J. Cancer, 12, 2055, 10.1016/0959-8049(92)90255-Z
Corbett, 1993, When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs, Chem. Res. Toxicol., 6, 585, 10.1021/tx00035a001
Chen, 1994, DNA topoisomerases: essential enzymes and lethal targets, Annu. Rev. Pharmacol. Toxicol., 34, 191, 10.1146/annurev.pa.34.040194.001203
L. Liu, DNA Topoisomerases: Topoisomerase-Targeted Drugs, Vol. 29, Academic Press, New York, 1994.
Froelich-Ammon, 1995, Topoisomerase poisons: harnessing the dark side of enzyme mechanism, J. Biol. Chem., 270, 21429, 10.1074/jbc.270.37.21429
Sinha, 1995, Topoisomerase inhibitors: a review of their therapeutic potential in cancer, Drugs, 49, 11, 10.2165/00003495-199549010-00002
Malonne, 1997, DNA topoisomerase targeting drugs: mechanisms of action and perspectives, Anti-Cancer Drugs, 8, 811, 10.1097/00001813-199710000-00001
Y. Pommier, in: B.A. Teicher (Ed.), Cancer Therapeutics: Experimental and Clinical Agents, Vol. I, Humana Press, Totowa, NJ, 1997, pp. 153–174.
Nelson, 1984, Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide, Proc. Natl. Acad. Sci. USA, 81, 1361, 10.1073/pnas.81.5.1361
Chen, 1984, Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II, J. Biol. Chem., 259, 13560, 10.1016/S0021-9258(18)90729-5
Ross, 1984, Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage, Cancer Res., 44, 5857
Robinson, 1991, Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage, J. Biol. Chem., 266, 14585, 10.1016/S0021-9258(18)98726-0
Elsea, 1993, Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential, Antimicrob. Agents Chemother., 37, 2179, 10.1128/AAC.37.10.2179
Miller, 1981, A homogeneous type II DNA topoisomerase from HeLa cell nuclei, J. Biol. Chem., 256, 9334, 10.1016/S0021-9258(19)52552-2
Shelton, 1983, DNA topoisomerase II from Drosophila melanogaster. Purification and physical characterization, J. Biol. Chem., 258, 9530, 10.1016/S0021-9258(17)44699-0
Goto, 1984, The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae, J. Biol. Chem., 259, 10422, 10.1016/S0021-9258(18)90981-6
Halligan, 1985, Purification and characterization of a type II DNA topoisomerase from bovine calf thymus, J. Biol. Chem., 260, 2475, 10.1016/S0021-9258(18)89578-3
Drake, 1987, Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme, J. Biol. Chem., 262, 16739, 10.1016/S0021-9258(18)49317-9
Sullivan, 1989, Purification and characterization of an altered topoisomerase II from a drugresistant Chinese hamster ovary cell line, Biochemistry, 28, 5680, 10.1021/bi00439a051
Saijo, 1990, Purification and characterization of type II DNA topoisomerase from mouse FM3A cells: phosphorylation of topoisomerase II and modification of its activity, Biochemistry, 29, 583, 10.1021/bi00454a036
Shiozaki, 1991, A functional 125-kDa core polypeptide of fission yeast DNA topoisomerase II, Mol. Cell. Biol., 11, 6093, 10.1128/MCB.11.12.6093
Lynn, 1986, Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase, Science, 233, 647, 10.1126/science.3014661
Wyckoff, 1989, Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II, J. Mol. Biol., 205, 1, 10.1016/0022-2836(89)90361-6
Worland, 1989, Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae, J. Biol. Chem., 264, 4412, 10.1016/S0021-9258(18)83757-7
Shiozaki, 1992, Functional dissection of the phosphorylated termini of fission yeast DNA topoisomerase II, J. Cell Biol., 119, 1023, 10.1083/jcb.119.5.1023
Crenshaw, 1993, Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. II. In vivo studies, J. Biol. Chem., 268, 21335, 10.1016/S0021-9258(19)36928-5
Mirski, 1995, Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line, Cancer Res., 55, 2129
Cardenas, 1992, Casein kinase II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in vivo, EMBO J., 11, 1785, 10.1002/j.1460-2075.1992.tb05230.x
Wells, 1994, Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro, J. Biol. Chem., 269, 29746, 10.1016/S0021-9258(18)43944-0
Caron, 1994, The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II, Mol. Cell. Biol., 14, 3197, 10.1128/MCB.14.5.3197
Crenshaw, 1993, Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. I. In vitro studies, J. Biol. Chem., 268, 21328, 10.1016/S0021-9258(19)36927-3
Goto, 1984, Yeast DNA topoisomerase II is encoded by a single-copy, essential gene, Cell, 36, 1073, 10.1016/0092-8674(84)90057-6
Drake, 1989, Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II, Biochemistry, 28, 8154, 10.1021/bi00446a029
Jenkins, 1992, Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24, Nucleic Acids Res., 20, 5587, 10.1093/nar/20.21.5587
Austin, 1993, Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases, Biochim. Biophys. Acta, 1172, 283, 10.1016/0167-4781(93)90215-Y
Capranico, 1992, Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development, Biochim. Biophys. Acta, 1132, 43, 10.1016/0167-4781(92)90050-A
Burden, 1994, Phosphorylation of the alpha- and beta-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells, Biochemistry, 33, 14651, 10.1021/bi00253a001
Watanabe, 1994, Differential expressions of the topoisomerase II alpha and II beta mRNAs in developing rat brain, Neurosci. Res., 19, 51, 10.1016/0168-0102(94)90007-8
Jensen, 1996, Human DNA topoisomerases II alpha and II beta can functionally substitute for yeast TOP2 in chromosome segregation and recombination, Mol. Gen. Genet., 252, 79, 10.1007/BF02173207
Meczes, 1997, Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast, Cancer Chemother. Pharmacol., 39, 367, 10.1007/s002800050585
Heck, 1988, Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle, Proc. Natl. Acad. Sci. USA, 85, 1086, 10.1073/pnas.85.4.1086
Woessner, 1991, Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells, Cell Growth Differ., 2, 209
Saijo, 1992, Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cells, Biochemistry, 31, 359, 10.1021/bi00117a007
Burden, 1993, Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II, Biochem. J., 293, 297, 10.1042/bj2930297
Kimura, 1994, Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase, J. Biol. Chem., 269, 1173, 10.1016/S0021-9258(17)42238-1
Heck, 1986, Topoisomerase II: A specific marker or cell proliferation, J. Cell Biol., 103, 2569, 10.1083/jcb.103.6.2569
Sullivan, 1987, Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents, Natl. Cancer Inst. Monogr., 4, 73
Sullivan, 1987, Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells, Cancer Res., 47, 3973
Hsiang, 1988, Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells, Cancer Res., 48, 3230
Biersack, 1996, Active heterodimers are formed from human DNA topoisomerase IIα and IIβ isoforms, Proc. Natl. Acad. Sci. USA, 93, 8288, 10.1073/pnas.93.16.8288
Osheroff, 1986, Eukaryotic topoisomerase II. Characterization of enzyme turnover, J. Biol. Chem., 261, 9944, 10.1016/S0021-9258(18)67607-0
Osheroff, 1987, Role of the divalent cation in topoisomerase II mediated reactions, Biochemistry, 26, 6402, 10.1021/bi00394a015
Sander, 1987, Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding, J. Mol. Biol., 194, 219, 10.1016/0022-2836(87)90370-6
Lee, 1989, Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites, J. Biol. Chem., 264, 21779, 10.1016/S0021-9258(20)88251-9
Thomsen, 1990, Characterization of the interaction between topoisomerase II and DNA by transcriptional footprinting, J. Mol. Biol., 215, 237, 10.1016/S0022-2836(05)80342-0
Howard, 1991, Drosophila topoisomerase II-DNA interactions are affected by DNA structure, J. Mol. Biol., 217, 53, 10.1016/0022-2836(91)90610-I
Bechert, 1994, Human 170 kDa and 180 kDa topoisomerases II bind preferentially to curved and left-handed linear DNA, J. Biomol. Struct. Dynam., 12, 605, 10.1080/07391102.1994.10508762
Zechiedrich, 1990, Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers, EMBO J., 9, 4555, 10.1002/j.1460-2075.1990.tb07908.x
Roca, 1993, On the simultaneous binding of eukaryotic DNA topoisomerase II to a pair of double-stranded DNA helices, J. Biol. Chem., 268, 14250, 10.1016/S0021-9258(19)85234-1
Roca, 1992, The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases, Cell, 71, 833, 10.1016/0092-8674(92)90558-T
Madden, 1995, Preferential binding of human topoisomerase I to superhelical DNA, EMBO J., 14, 5399, 10.1002/j.1460-2075.1995.tb00224.x
Corbett, 1992, Effect of casein kinase IImediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis, J. Biol. Chem., 267, 20513, 10.1016/S0021-9258(19)88732-X
Dang, 1994, Phosphorylation of the C-terminal domain of yeast topoisomerase II by casein kinase II affects DNA-protein interaction, J. Mol. Biol., 243, 10, 10.1006/jmbi.1994.1626
Osheroff, 1987, Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form, Biochemistry, 26, 4303, 10.1021/bi00388a018
Andersen, 1989, Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction, Biochemistry, 28, 6237, 10.1021/bi00441a015
Muller, 1988, Single-strand DNA cleavages by eukaryotic topoisomerase II, Biochemistry, 27, 8369, 10.1021/bi00422a012
Sander, 1985, Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site, Nucleic Acids Res., 13, 1057, 10.1093/nar/13.4.1057
Spitzner, 1988, A consensus sequence for cleavage by vertebrate DNA topoisomerase II, Nucleic Acids Res., 16, 5533, 10.1093/nar/16.12.5533
Pommier, 1991, Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs, J. Mol. Biol., 222, 909, 10.1016/0022-2836(91)90585-T
Sperry, 1989, Dysfunction of chromosomal loop attachment sites: illegitimate recombination linked to matrix association regions and topoisomerase II, Proc. Natl. Acad. Sci. USA, 86, 5497, 10.1073/pnas.86.14.5497
Cornarotti, 1996, Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180), Mol. Pharmacol., 50, 1463
Capranico, 1990, Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin, Nucleic Acids Res., 18, 6611, 10.1093/nar/18.22.6611
Spitzner, 1990, Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats, Nucleic Acids Res., 18, 1, 10.1093/nar/18.1.1
Froelich-Ammon, 1994, Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage, J. Biol. Chem., 269, 7719, 10.1016/S0021-9258(17)37346-5
Arndt-Jovin, 1993, Z-DNA binding and inhibition by GTP of Drosophila topoisomerase II, Biochemistry, 32, 4862, 10.1021/bi00069a023
Chung, 1992, Eukaryotic topoisomerase II cleavage of parallel stranded DNA tetraplexes, Nucleic Acids Res., 20, 1973, 10.1093/nar/20.8.1973
Corbett, 1992, A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage, J. Biol. Chem., 267, 683, 10.1016/S0021-9258(18)48335-4
Wigley, 1991, Crystal structure of an N-terminal fragment of the DNA gyrase B protein, Nature, 351, 624, 10.1038/351624a0
Ali, 1995, Nucleotide binding to the 43-kilodalton N-terminal fragment of the DNA gyrase B protein, Biochemistry, 34, 9801, 10.1021/bi00030a018
Berger, 1996, Recent developments in DNA topoisomerase II structure and mechanism, Curr. Opin. Struct. Biol., 6, 84, 10.1016/S0959-440X(96)80099-6
Benedetti, 1983, Purification and characterization of Xenopus laevis topoisomerase II, EMBO J., 2, 1303, 10.1002/j.1460-2075.1983.tb01585.x
Schomburg, 1986, Purification and characterization of DNA topoisomerase II from calf thymus associated with polypeptides of 175 and 150 kDa, Eur. J. Biochem., 160, 451, 10.1111/j.1432-1033.1986.tb10061.x
Roca, 1996, DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism, Proc. Natl. Acad. Sci. USA, 93, 4057, 10.1073/pnas.93.9.4057
Lindsley, 1996, Intradimerically tethered DNA topoisomerase II is catalytically active in DNA transport, Proc. Natl. Acad. Sci. USA, 93, 2975, 10.1073/pnas.93.7.2975
E.L. Zechiedrich, Doctoral Dissertation in Biochemistry, Vanderbilt University, Nashville, TN, 1990.
Roca, 1994, DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism, Cell, 77, 609, 10.1016/0092-8674(94)90222-4
Robinson, 1991, Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II, Biochemistry, 30, 1807, 10.1021/bi00221a012
Lindsley, 1993, On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II, J. Biol. Chem., 268, 8096, 10.1016/S0021-9258(18)53067-2
Corbett, 1993, Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation, Biochemistry, 32, 2090, 10.1021/bi00059a029
R.L. Stevenson, The Strange Case of Dr. Jekyll and Mr. Hyde, Longmans, Greene, and Co., London, 1886.
Kohn, 1996, DNA filter elution: a window on DNA damage in mammalian cells, BioEssays, 18, 505, 10.1002/bies.950180613
Ferguson, 1994, Topoisomerase II enzymes and mutagenicity, Environ. Mol. Mutagen., 24, 245, 10.1002/em.2850240402
Holm, 1989, Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells, Cancer Res., 49, 6365
D’Arpa, 1990, Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons, Cancer Res., 50, 6919
Howard, 1994, Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase, Proc. Natl. Acad. Sci. USA, 91, 12031, 10.1073/pnas.91.25.12031
Bae, 1988, Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro, Proc. Natl. Acad. Sci. USA, 85, 2076, 10.1073/pnas.85.7.2076
Nitiss, 1988, DNA topoisomerase-targeting antitumor drugs can be studied in yeast, Proc. Natl. Acad. Sci. USA, 85, 7501, 10.1073/pnas.85.20.7501
Andersson, 1989, The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA, Carcinogenesis, 10, 123, 10.1093/carcin/10.1.123
DeVore, 1989, Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q, Ann. Intern. Med., 110, 740, 10.7326/0003-4819-110-9-740
Lonn, 1989, Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide), Cancer Res., 49, 6202
Charron, 1990, DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4′-demethylepipodophyllotoxin 9-(4,6-O-thenylidene-beta-D-glucopyranoside), Biochemistry, 29, 9531, 10.1021/bi00493a006
Han, 1993, Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro, J. Mol. Biol., 229, 52, 10.1006/jmbi.1993.1007
Solary, 1994, Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. [Review], Leuk. Lymph., 15, 21, 10.3109/10428199409051674
Chen, 1994, Mechanisms of resistance to topoisomerase inhibitors, Cancer Treat. Res., 73, 263, 10.1007/978-1-4615-2632-2_13
DeVore, 1992, Chronic oral etoposide in the treatment of small cell lung cancer, Semin. Oncol., 19, 40
Belani, 1994, Etoposide: current status and future perspectives in the management of malignant neoplasms, Cancer Chemother. Pharmacol., 34, S118, 10.1007/BF00684875
Y. Pommier, M.R. Fesen, F. Goldwasser, in: B.A. Chabner, D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edn., Lippincott-Raven, Philadelphia, PA, 1996, pp. 435–461.
B.A. Chabner, in: V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practice of Oncology, 4th edn., J.B. Lippincott Co., Philadelphia, PA, 1993, pp. 325–417.
Barnes, 1995, Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer, J. Cell. Biochem. Suppl., 22, 181, 10.1002/jcb.240590823
Stoll, 1997, Eating to beat breast cancer: Potential role for soy supplements, Ann. Oncol., 8, 223, 10.1023/A:1008237505645
Maxwell, 1992, The molecular basis of quinolone action. [Review], J. Antimicrob. Chemother., 30, 409, 10.1093/jac/30.4.409
Robinson, 1992, Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group, Antimicrob. Agents Chemother., 36, 751, 10.1128/AAC.36.4.751
T. Gootz, N. Osheroff, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society of Microbiology, Washington, DC, 1993, pp. 139–160.
Hooper, 1991, Fluoroquinolone antimicrobial agents, New Engl. J. Med., 324, 384, 10.1056/NEJM199102073240606
D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society of Microbiology, Washington, DC, 1993.
L.F. Liu, P. D’Arpa, Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance, Important Adv. Oncol. (1992) 79–89.
Pommier, 1994, Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors, Cancer Invest., 12, 530, 10.3109/07357909409021413
Kreuzer, 1979, Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth, J. Bacteriol., 140, 424, 10.1128/JB.140.2.424-435.1979
Webb, 1991, Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line, Cancer Res., 51, 6543
Nitiss, 1992, Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II, Cancer Res., 52, 4467
Qiu, 1996, Formation of topoisomerase IIα complexes with nascent DNA is related to VM-26-induced cytotoxicity, Biochemistry, 35, 16354, 10.1021/bi9619637
Brown, 1995, Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines, Cancer Res., 55, 78
Beck, 1993, Drug resistance associated with altered DNA topoisomerase II, Adv. Enzyme Regul., 33, 113, 10.1016/0065-2571(93)90012-3
Vassetzky, 1995, DNA topoisomerase II mutations and resistance to anti-tumor drugs, BioEssays, 17, 767, 10.1002/bies.950170906
Nitiss, 1996, Antitopoisomerase drug action and resistance, Eur. J. Cancer, 32a, 958, 10.1016/0959-8049(96)00056-1
Hsiung, 1995, A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria, J. Biol. Chem., 270, 20359, 10.1074/jbc.270.35.20359
Zwelling, 1989, Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drugresistant form of topoisomerase II, J. Biol. Chem., 264, 16411, 10.1016/S0021-9258(19)84722-1
Bugg, 1991, Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide, Proc. Natl. Acad. Sci. USA, 88, 7654, 10.1073/pnas.88.17.7654
Mayes, 1993, Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target, Biochem. Pharmacol., 46, 699, 10.1016/0006-2952(93)90557-D
Elsea, 1995, A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine, J. Biol. Chem., 270, 1913, 10.1074/jbc.270.4.1913
Corbett, 1993, Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme, J. Biol. Chem., 268, 14394, 10.1016/S0021-9258(19)85252-3
Osheroff, 1994, Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes, Cancer Chemother. Pharmacol., 34, S19, 10.1007/BF00684859
Elsea, 1997, Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs, Biochemistry, 36, 2919, 10.1021/bi962488f
Freudenreich, 1994, Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex, Proc. Natl. Acad. Sci. USA, 91, 11007, 10.1073/pnas.91.23.11007
Pommier, 1991, Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide, Nucleic Acids Res., 19, 5973, 10.1093/nar/19.21.5973
Capranico, 1993, Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II, Biochemistry, 32, 3038, 10.1021/bi00063a015
Osheroff, 1989, Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide, Biochemistry, 28, 6157, 10.1021/bi00441a005
Robinson, 1990, Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino)methanesulfon-m-anisidide, Biochemistry, 29, 2511, 10.1021/bi00462a012
Sørensen, 1992, Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events, J. Mol. Biol., 228, 778, 10.1016/0022-2836(92)90863-F
Burden, 1996, Topoisomerase II·etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes, J. Biol. Chem., 271, 29238, 10.1074/jbc.271.46.29238
Froelich-Ammon, 1995, Topoisomerase II binds to ellipticine in the absence or presence of DNA: characterization of enzyme-drug interactions by fluorescence spectroscopy, J. Biol. Chem., 270, 14998, 10.1074/jbc.270.25.14998
Cline, 1997, Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine, Biochemistry, 36, 13095, 10.1021/bi971770z
Kingma, 1997, Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage, J. Biol. Chem., 272, 7488, 10.1074/jbc.272.11.7488
Kingma, 1997, Apurinic sites are position-specific topoisomerase II-poisons, J. Biol. Chem., 272, 1148, 10.1074/jbc.272.2.1148
Hertzberg, 1989, On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex, Biochemistry, 28, 4629, 10.1021/bi00437a018
Shen, 1989, Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes, J. Biol. Chem., 264, 2973, 10.1016/S0021-9258(19)81708-8
Willmott, 1993, A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex, Antimicrob. Agents Chemother., 37, 126, 10.1128/AAC.37.1.126
Yoshida, 1993, Mechanism of action of quinolones against Escherichia coli DNA gyrase, Antimicrob. Agents Chemother., 37, 839, 10.1128/AAC.37.4.839